abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Decrease in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 54,047 shares, a decline of 34.6% from the November 30th total of 82,698 shares. Based on an average daily volume of 122,447 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 122,447 shares, the short-interest ratio is presently 0.4 days.

abrdn Life Sciences Investors Price Performance

NYSE HQL traded down $0.20 on Tuesday, hitting $16.81. The company had a trading volume of 159,928 shares, compared to its average volume of 114,700. abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $17.80. The company’s fifty day moving average price is $17.02 and its 200-day moving average price is $15.04.

abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, January 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, November 21st. This represents a $2.00 annualized dividend and a dividend yield of 11.9%. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.42.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Institutional investors and hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its stake in abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the period. Cornerstone Advisors LLC purchased a new stake in shares of abrdn Life Sciences Investors during the third quarter worth $175,000. Stephens Inc. AR raised its stake in shares of abrdn Life Sciences Investors by 9.8% in the second quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock valued at $272,000 after acquiring an additional 1,895 shares in the last quarter. Samalin Investment Counsel LLC boosted its holdings in abrdn Life Sciences Investors by 6.7% in the second quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock valued at $279,000 after purchasing an additional 1,366 shares during the period. Finally, KPP Advisory Services LLC grew its stake in abrdn Life Sciences Investors by 7.7% during the 2nd quarter. KPP Advisory Services LLC now owns 23,555 shares of the company’s stock worth $302,000 after purchasing an additional 1,681 shares in the last quarter. 32.21% of the stock is currently owned by institutional investors and hedge funds.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.